Benchoufi Mehdi, Bokobza Jerôme, Chauvin Anthony, Dion Elisabeth, Baranne Marie-Laure, Levan Fabien, Gautier Maxime, Cantin Delphine, d'Humières Thomas, Gil-Jardiné Cédric, Benenati Sylvain, Orbelin Mathieu, Martinez Mikaël, Pierre-Kahn Nathalie, Diallo Abdourahmane, Vicaut Eric, Bourrier Pierre
Center for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
METHODS Team, Center for Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS-UMR 1153), Paris, France.
J Ultrasound Med. 2023 Dec;42(12):2883-2895. doi: 10.1002/jum.16329. Epub 2023 Sep 9.
Chest CT is the reference test for assessing pulmonary injury in suspected or diagnosed COVID-19 with signs of clinical severity. This study aimed to evaluate the association of a lung ultrasonography score and unfavorable clinical evolution at 28 days.
The eChoVid is a multicentric study based on routinely collected data that was conducted in 8 emergency units in France; patients were included between March 19, 2020 and April 28, 2020 and underwent lung ultrasonography, a short clinical assessment by 2 emergency physicians blinded to each other's assessment, and chest CT. Lung ultrasonography consisted of scoring lesions from 0 to 3 in 8 chest zones, thus defining a global score (GS) of severity from 0 to 24. The primary outcome was the association of lung damage severity as assessed by the GS at day 0 and patient status at 28 days. Secondary outcomes were comparing the performance between GS and CT scan and the performance between a new trainee physician and an ultrasonography expert in scores.
For the 328 patients analyzed, the GS showed good performance in predicting clinical worsening at 28 days (area under the receiver operating characteristic curve [AUC] 0.83, sensitivity 84.2%, specificity 76.4%). The GS showed good performance in predicting the CT severity assessment (AUC 0.84, sensitivity 77.2%, specificity 83.7%).
A lung ultrasonography GS is a simple tool that can be used in the emergency department to predict unfavorable assessment at 28 days in patients with COVID-19.
胸部CT是评估疑似或确诊的COVID-19且有临床严重体征患者肺部损伤的参考检查。本研究旨在评估肺部超声评分与28天不良临床进展之间的关联。
eChoVid是一项基于常规收集数据的多中心研究,在法国的8个急诊科开展;研究纳入了2020年3月19日至2020年4月28日期间的患者,这些患者均接受了肺部超声检查、由两名彼此不知情的急诊科医生进行的简短临床评估以及胸部CT检查。肺部超声检查包括对8个胸部区域的病变从0至3分进行评分,从而确定0至24分的整体严重程度评分(GS)。主要结局是第0天通过GS评估的肺损伤严重程度与28天时患者状态之间的关联。次要结局是比较GS与CT扫描之间的性能,以及新实习医生和超声专家在评分方面的性能。
对于分析的328例患者,GS在预测28天临床恶化方面表现良好(受试者工作特征曲线下面积[AUC]为0.83,敏感性为84.2%,特异性为76.4%)。GS在预测CT严重程度评估方面表现良好(AUC为0.84,敏感性为77.2%,特异性为83.7%)。
肺部超声GS是一种简单的工具,可在急诊科用于预测COVID-19患者28天的不良评估。